Linnaeus

Linnaeus Therapeutics, Inc. is a clinical-stage, biotechnology company headquartered in Philadelphia, Pennsylvania. The company was launched through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Linnaeus has licensed key enabling worldwide patents from the University of Pennsylvania (“Penn”) and the University of New Mexico (“UNM”) for compounds and methods for the treatment of cancer. Linnaeus has also filed patents of its own on its lead compound LNS8801, which extend the value of Linnaeus’s licensed patent portfolio. Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways. Year Founded: 2016 Key Executives: • Patrick Mooney, MD CEO • Tina Garyantes, PhD, SVP R&D • Chris Natale, PhD Founder and Director of Research Location: Philadelphia, PA Website: http://linnaeustx.com/ Company Status: Private Year Invested: 2018 Investment Status: Current Board Members: • Neil Patel • Todd Thomson Linnaeus Therapeutics announced the presentation of clinical data from its phase 1 dose-expansion study of LNS8801... Linnaeus Therapeutics announced that the FDA has granted orphan drug designation for LNS8801 for the treatment... Linnaeus Therapeutics, Inc. announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S.... Linnaeus Therapeutics announced the presentation of clinical biomarker data from its study of LNS8801 as a... Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1/2 clinical trial of... Linnaeus Therapeutics, Inc. announced that the laboratory of Gary Schwartz, MD at Columbia University Irving Medical Center... Linnaeus Therapeutics announced it has been awarded a Phase 2 Bridge Small Business Innovation Research ("SBIR")... Linnaeus Therapeutics announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional... Copyright © 2024 Kairos Venture Investments, LLC.